Abstract
We recently obtained evidence that treatment of human colon cancer cells with exisulind (sulindac sulfone) and related compounds induces apoptosis by activation of protein kinase G (PKG) and c-Jun kinase (JNK1). The present study further explores this mechanism. We demonstrate that in NIH3T3 cells a constitutively active mutant of PKG causes a dose-dependent activation of JNK1 and thereby transactivates c-Jun and stimulates transcription from the AP-1 enhancer element. The activation of JNK1 and the transactivation of c-Jun by this mutant of PKG were inhibited by a dominant negative MEKK1. In vitro assays showed that a purified PKG directly phosphorylated the N-terminal domain of MEKK1. PKG also directly phosphorylated a full-length MEKK1, and this was associated with enhanced MEKK1 phosphorylation. Thus, it appears that PKG activates JNK1 through a novel PKG-MEKK1-SEK1-JNK1 pathway, by directly phosphorylating and activating MEKK1.
Cite
CITATION STYLE
Soh, J. W., Mao, Y., Liu, L., Thompson, W. J., Pamukcu, R., & Weinstein, I. B. (2001). Protein Kinase G Activates the JNK1 Pathway via Phosphorylation of MEKK1. Journal of Biological Chemistry, 276(19), 16406–16410. https://doi.org/10.1074/jbc.C100079200
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.